SCHEMBL6135967

SCHEMBL6135967

CC(C)n1nc(C(=CN(C)C)C(=O)c2ccc(C(F)(F)F)cc2)ccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.42
CYP11B2 P19099 4/20 0.42
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
LIPE Q05469 1/20 0.34
NR4A1 P22736 1/20 0.33
NR4A2 P43354 1/20 0.33
NR4A3 Q92570 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GSK3B P49841 1/20 0.32
SLC6A4 P31645 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
BRD4 O60885 1/20 0.32
OPRM1 P35372 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135964 1.00 CYP11B1 (0.42) CYP11B1CYP11B2CES2CES1ADORA3
SCHEMBL6133711 0.88 CYP1A2 (0.35) CES2CES1ADORA2AADORA1NPC1
SCHEMBL6133710 0.88 CYP1A2 (0.35) CES2CES1ADORA2AADORA1NPC1
SCHEMBL6135116 0.88 CES2 (0.43) CES2NPC1RAB9AOPRM1TSHR
SCHEMBL6135115 0.88 CES2 (0.43) CES2NPC1RAB9AOPRM1TSHR
SCHEMBL6134296 0.85 LMNA (0.40) CES2CES1ADORA3ADORA2AADORA1
SCHEMBL6134293 0.85 LMNA (0.40) CES2CES1ADORA3ADORA2AADORA1
SCHEMBL6134014 0.81 CNR2 (0.35) CYP11B1CYP11B2SLC6A4
SCHEMBL6134547 0.80 CES2 (0.40) CES2CES1GSK3BOPRM1
SCHEMBL6134543 0.80 CES2 (0.40) CES2CES1GSK3BOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 CYP11B1 808/4885CYP11B2 673/4885CES2 4034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.